Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.

Turner HC, Baussano I, Garnett GP.

PLoS One. 2013 Sep 26;8(9):e75552. doi: 10.1371/journal.pone.0075552. eCollection 2013.

3.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

4.

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.

Bogaards JA, Coupé VM, Meijer CJ, Berkhof J.

Vaccine. 2011 Nov 8;29(48):8929-36. doi: 10.1016/j.vaccine.2011.09.055. Epub 2011 Sep 22.

PMID:
21945961
5.

Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.

Kim JJ.

Lancet Infect Dis. 2010 Dec;10(12):845-52. doi: 10.1016/S1473-3099(10)70219-X. Epub 2010 Nov 2.

6.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

7.

Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.

Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.

Vaccine. 2015 May 7;33 Suppl 1:A167-73. doi: 10.1016/j.vaccine.2014.12.067.

PMID:
25919157
8.

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

PLoS One. 2014 Mar 20;9(3):e89974. doi: 10.1371/journal.pone.0089974. eCollection 2014.

9.

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.

Jit M, Chapman R, Hughes O, Choi YH.

BMJ. 2011 Sep 27;343:d5775. doi: 10.1136/bmj.d5775.

10.

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.

Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.

Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3.

PMID:
23830974
11.

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N.

BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.

12.

Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

J Infect Dis. 2015 Jan 15;211(2):206-15. doi: 10.1093/infdis/jiu413. Epub 2014 Jul 23.

13.

A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.

Bresse X, Adam M, Largeron N, Roze S, Marty R.

Hum Vaccin Immunother. 2013 Apr;9(4):823-33. doi: 10.4161/hv.22994. Epub 2013 Apr 1.

14.

The role of optimal control in assessing the most cost-effective implementation of a vaccination programme: HPV as a case study.

Brown VL, Jane White KA.

Math Biosci. 2011 Jun;231(2):126-34. doi: 10.1016/j.mbs.2011.02.009. Epub 2011 Mar 4.

PMID:
21377481
15.

Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.

Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagón T, Brisson M.

Vaccine. 2014 Oct 7;32(44):5845-53. doi: 10.1016/j.vaccine.2014.07.099. Epub 2014 Aug 12.

16.

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening.

Coupé VM, Bogaards JA, Meijer CJ, Berkhof J.

Vaccine. 2012 Feb 27;30(10):1813-22. doi: 10.1016/j.vaccine.2012.01.001. Epub 2012 Jan 10.

PMID:
22240341
17.

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.

PMID:
20085477
18.

National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.

Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5107-12. doi: 10.1073/pnas.1515528113. Epub 2016 Apr 18.

19.

Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.

Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.

Vaccine. 2013 Aug 20;31(37):3922-7. doi: 10.1016/j.vaccine.2013.06.044. Epub 2013 Jun 24.

PMID:
23806241
20.

Cost–effectiveness of catch-up programs in human papillomavirus vaccination.

de Peuter MA, Littlewood KJ, Annemans L, Largeron N, Quilici S.

Expert Rev Vaccines. 2010 Oct;9(10):1187-201. doi: 10.1586/erv.10.108. Review.

PMID:
20923269

Supplemental Content

Support Center